Merck Gets China Nod on HPV Shot for Men
Merck's HPV Vaccine Gains Ground in China
U.S. drugmaker Merck & Co has received approval in China for its HPV vaccine's use in males, expanding its market reach despite earlier weak sales in the region. This move marks a potential growth opportunity as Gardasil has been key to Merck's market strategy alongside cancer treatment Keytruda.
Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
This was the stock's second consecutive day of gains.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
U.S. drugmaker Merck & Co said on Wednesday (January 8, 2025) that its human papillomavirus (HPV) vaccine for men has been ...
24/7 Wall St. on MSN8h
Merck Just Paid Investors: How Much Did They Receive?Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback